|
94 Companies |
|
165 Products |
|
165 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
1453 News |
|
| «12...345678910111213...2930» |
- || Enrollment closed, Adherence: Improving Adherence to Statins Among Minority Populations (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=800, Active, not recruiting, Sponsor: University of Miami
Recruiting --> Active, not recruiting
- metformin / Generic mfg., pioglitazone / Generic mfg.
Enrollment closed: Metabolic Abnormalities in HIV-infected Persons (clinicaltrials.gov) - Apr 30, 2015
P4, N=70, Active, not recruiting, Sponsor: Tufts Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Trial completion, Trial primary completion date: RxACT: A Community Based Approach to Dyslipidemia Management: Pharmacist Prescribing to Achieve Cholesterol Targets (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=100, Completed, Sponsor: University of Alberta
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jan 2013
- |||| bococizumab (RN316) / Pfizer
Trial primary completion date: SPIRE-FH: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Apr 27, 2015
P3, N=300, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Completed | Trial primary completion date: Jul 2012 --> Jan 2013 Trial primary completion date: Mar 2015 --> Mar 2016
- Enrollment closed, Trial primary completion date: Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders (clinicaltrials.gov) - Apr 25, 2015
P2, N=66, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Mar 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Jun 2015
- |||||| bococizumab (RN316) / Pfizer
Enrollment open: SPIRE-HR: Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Apr 23, 2015
P3, N=600, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Jun 2015 Active, not recruiting --> Recruiting
- bococizumab (RN316) / Pfizer
Enrollment change: Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia (clinicaltrials.gov) - Apr 23, 2015
P1, N=0, Withdrawn, Sponsor: Pfizer
Active, not recruiting --> Recruiting N=91 --> 0
- ||||| evacetrapib (LY2484595) / Eli Lilly
Enrollment closed: A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia (clinicaltrials.gov) - Apr 23, 2015
P3, N=52, Active, not recruiting, Sponsor: Eli Lilly and Company
N=91 --> 0 Recruiting --> Active, not recruiting
- Trial withdrawal: A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia (clinicaltrials.gov) - Apr 22, 2015
P1, N=0, Withdrawn, Sponsor: Avera McKennan Hospital & University Health Center
Recruiting --> Active, not recruiting Terminated --> Withdrawn
- |||||| bococizumab (RN316) / Pfizer
Enrollment open: SPIRE-SI: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (clinicaltrials.gov) - Apr 21, 2015
P3, N=150, Recruiting, Sponsor: Pfizer
Terminated --> Withdrawn Active, not recruiting --> Recruiting
- Trial primary completion date: Effects of Almond Intake on Atherogenic Lipoprotein Particles (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=40, Recruiting, Sponsor: Children's Hospital & Research Center Oakland
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- Trial primary completion date: Outer Thigh Study With Varied Treatment Parameters (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: Zeltiq Aesthetics
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Nov 2014 --> Jun 2015
- || Trial primary completion date: Telephone Based Management of Hyperlipidemia (clinicaltrials.gov) - Apr 15, 2015
P4, N=100, Recruiting, Sponsor: Temple University
Trial primary completion date: Nov 2014 --> Jun 2015 Trial primary completion date: Jan 2015 --> Jul 2015
- | Juxtapid (lomitapide) / Novelion, Chiesi
Trial primary completion date: Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Apr 14, 2015
P3, N=19, Completed, Sponsor: Aegerion Pharmaceuticals, Inc.
Trial primary completion date: Jan 2015 --> Jul 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- Glybera (alipogene tiparvovec) / uniQure, Chiesi, Xenon
Trial termination, Trial primary completion date: Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=19, Terminated, Sponsor: Amsterdam Molecular Therapeutics
Trial primary completion date: Dec 2013 --> Dec 2014 Suspended --> Terminated | Trial primary completion date: Jan 2013 --> Sep 2012; Business reason
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: ODYSSEY OLE: Open Label Study of Long Term Safety Evaluation of Alirocumab (clinicaltrials.gov) - Apr 14, 2015
P3, N=1200, Enrolling by invitation, Sponsor: Sanofi
Suspended --> Terminated | Trial primary completion date: Jan 2013 --> Sep 2012; Business reason Trial primary completion date: Jun 2016 --> Jun 2017
- Praluent (alirocumab) / Sanofi, Regeneron
Enrollment closed: Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol (clinicaltrials.gov) - Apr 10, 2015
P1, N=21, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Active, not recruiting
- ||| Parmodia (pemafibrate) / Kowa
Trial completion: A Thorough Corrected QT Interval Trial (clinicaltrials.gov) - Apr 10, 2015
P1, N=56, Completed, Sponsor: Kowa Research Institute, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| rosuvastatin / Generic mfg.
Enrollment change: An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia (clinicaltrials.gov) - Apr 7, 2015
P3, N=315, Completed, Sponsor: AstraZeneca
Recruiting --> Completed N=250 --> 315
- Enrollment change: Effects of Vitamin D on Lipids (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=130, Completed, Sponsor: University of California, San Francisco
N=250 --> 315 N=45 --> 130
- ezetimibe / Generic mfg.
Trial completion: PRECISE-IVUS: Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (clinicaltrials.gov) - Apr 1, 2015
P4, N=245, Completed, Sponsor: Kumamoto University
N=45 --> 130 Active, not recruiting --> Completed
- | Replagal (agalsidase alfa) / Samaritan Pharma, Takeda
Trial completion: Dosing Study of Replagal in Patients With Fabry Disease (clinicaltrials.gov) - Mar 31, 2015
P2, N=13, Completed, Sponsor: Baylor Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| bococizumab (RN316) / Pfizer
Enrollment closed, Trial primary completion date: SPIRE-FH: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Mar 31, 2015
P3, N=300, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2015
- |||| AEM-28 / Capstone
Trial completion: Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia (clinicaltrials.gov) - Mar 31, 2015
P1/2, N=52, Completed, Sponsor: LipimetiX Development, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2015 Recruiting --> Completed
- |||| Fabrazyme (agalsidase beta) / Sanofi
Trial completion: A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease (clinicaltrials.gov) - Mar 31, 2015
P4, N=67, Completed, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Completed No longer recruiting --> Completed
- | Fabrazyme (agalsidase beta) / Sanofi
Trial completion: A Study of Fabrazyme in Pediatric Patients With Fabry Disease (clinicaltrials.gov) - Mar 31, 2015
P2, N=16, Completed, Sponsor: Genzyme, a Sanofi Company
No longer recruiting --> Completed No longer recruiting --> Completed
- Enrollment closed: Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent. (clinicaltrials.gov) - Mar 27, 2015
P=N/A, N=60, Active, not recruiting, Sponsor: McGill University Health Center
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion, Trial primary completion date: Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=36, Completed, Sponsor: Children's Hospital & Research Center Oakland
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Aug 2013 --> Dec 2013
- ||||| bococizumab (RN316) / Pfizer
Enrollment closed: SPIRE-SI: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (clinicaltrials.gov) - Mar 25, 2015
P3, N=150, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Completed | Trial primary completion date: Aug 2013 --> Dec 2013 Recruiting --> Active, not recruiting
- atorvastatin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia (clinicaltrials.gov) - Mar 25, 2015
P1/2, N=28, Completed, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=40 --> 28 | Trial primary completion date: Apr 2014 --> Dec 2014
- Tredaptive (niacin controlled release/laropiprant) / Merck (MSD)
Enrollment change: Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors (clinicaltrials.gov) - Mar 24, 2015
P4, N=0, Withdrawn, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Active, not recruiting --> Completed | N=40 --> 28 | Trial primary completion date: Apr 2014 --> Dec 2014 N=100 --> 0
- Juxtapid (lomitapide) / Novelion, Chiesi
Enrollment closed, Trial primary completion date: Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy (clinicaltrials.gov) - Mar 24, 2015
P3, N=10, Active, not recruiting, Sponsor: Aegerion Pharmaceuticals, Inc.
N=100 --> 0 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015
- || Juxtapid (lomitapide) / Novelion, Chiesi
Trial completion, Enrollment change: Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Mar 19, 2015
P3, N=19, Completed, Sponsor: Aegerion Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed | N=25 --> 19
- ||||||| Repatha (evolocumab) / Amgen, Astellas
Trial completion, Combination therapy: FLOREY: Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (clinicaltrials.gov) - Mar 18, 2015
P3, N=89, Completed, Sponsor: Amgen
Active, not recruiting --> Completed | N=25 --> 19 Active, not recruiting --> Completed
- ||| Trial completion: A Human Trial to Assess the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Soy (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=243, Completed, Sponsor: Guelph Food Research Centre
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Myalept (metreleptin) / Novelion
Trial completion: An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=41, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Completed Active, not recruiting --> Completed
- ||||||| anacetrapib (MK-0859) / Merck (MSD)
Trial completion: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) (clinicaltrials.gov) - Mar 12, 2015
P3, N=307, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2 (clinicaltrials.gov) - Mar 10, 2015
P3, N=12, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Recruiting --> Completed | N=10 --> 12
- Trial completion: Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=14, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Completed | N=10 --> 12 Recruiting --> Completed
- tilarginine (L-NMMA) / Arginox Pharma, Houston Methodist Research Institute
Trial suspension, Trial primary completion date: Endothelial Hyperpolarization in Humans (clinicaltrials.gov) - Mar 9, 2015
P2, N=60, Suspended, Sponsor: Emory University
Recruiting --> Completed Recruiting --> Suspended | Trial primary completion date: Jun 2021 --> Jan 2015
- Trial completion: AVAG: Effect of Apples on cardioVascular Risk And Gut Health (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=40, Completed, Sponsor: University of Reading
Recruiting --> Suspended | Trial primary completion date: Jun 2021 --> Jan 2015 Recruiting --> Completed
- Trial primary completion date, HEOR: The Health Outcomes Management and Evaluation (HOME) Study (clinicaltrials.gov) - Mar 7, 2015
P3, N=400, Active, not recruiting, Sponsor: Emory University
Recruiting --> Completed Trial primary completion date: Sep 2014 --> Jul 2015
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Enrollment status: ODYSSEY OLE: Open Label Study of Long Term Safety Evaluation of Alirocumab (clinicaltrials.gov) - Mar 7, 2015
P3, N=1200, Enrolling by invitation, Sponsor: Sanofi
Trial primary completion date: Sep 2014 --> Jul 2015 Recruiting --> Enrolling by invitation
- Enrollment closed, Trial primary completion date: Effect of Age on Glucose and Lipid Metabolism (clinicaltrials.gov) - Mar 5, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015
- Enrollment closed: RRR: Reducing Risk of Recurrence (clinicaltrials.gov) - Mar 5, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- | PF-06427878 / Pfizer
Trial completion: A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects (clinicaltrials.gov) - Mar 5, 2015
P1, N=16, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| bococizumab (RN316) / Pfizer
Enrollment closed: SPIRE-HR: Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Mar 3, 2015
P3, N=600, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Trial completion, Enrollment change, Trial primary completion date: Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study. (clinicaltrials.gov) - Mar 3, 2015
P=N/A, N=52, Completed, Sponsor: University of Zurich
Recruiting --> Active, not recruiting Recruiting --> Completed | N=40 --> 52 | Trial primary completion date: Sep 2014 --> Jan 2015
- Trial completion, Trial primary completion date: Lipidown: Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=75, Completed, Sponsor: Nestlé
Recruiting --> Completed | N=40 --> 52 | Trial primary completion date: Sep 2014 --> Jan 2015 Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Oct 2014
- Myalept (metreleptin) / Novelion
Trial completion, Trial primary completion date: Leptin to Treat Lipodystrophy (clinicaltrials.gov) - Feb 23, 2015
P2, N=105, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Oct 2014 Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Feb 2015